While NGAL does not interfere with doxorubicin resistance in breast cancer cells [78], it might contribute to erlotinib (a tyrosine kinase inhibitor of the epidermal growth factor (EGF) receptor) resistance in non-small cell lung cancer cells [80]. This evidence concerns the gene LCN2 and breast carcinoma.